Hajjo Rima, Sabbah Dima A, Tropsha Alexander
Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733, Jordan.
Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pathogens. 2022 Jun 29;11(7):743. doi: 10.3390/pathogens11070743.
COVID-19 vaccines have been instrumental tools in reducing the impact of SARS-CoV-2 infections around the world by preventing 80% to 90% of hospitalizations and deaths from reinfection, in addition to preventing 40% to 65% of symptomatic illnesses. However, the simultaneous large-scale vaccination of the global population will indubitably unveil heterogeneity in immune responses as well as in the propensity to developing post-vaccine adverse events, especially in vulnerable individuals. Herein, we applied a systems biology workflow, integrating vaccine transcriptional signatures with chemogenomics, to study the pharmacological effects of mRNA vaccines. First, we derived transcriptional signatures and predicted their biological effects using pathway enrichment and network approaches. Second, we queried the Connectivity Map (CMap) to prioritize adverse events hypotheses. Finally, we accepted higher-confidence hypotheses that have been predicted by independent approaches. Our results reveal that the mRNA-based BNT162b2 vaccine affects immune response pathways related to interferon and cytokine signaling, which should lead to vaccine success, but may also result in some adverse events. Our results emphasize the effects of BNT162b2 on calcium homeostasis, which could be contributing to some frequently encountered adverse events related to mRNA vaccines. Notably, cardiac side effects were signaled in the CMap query results. In summary, our approach has identified mechanisms underlying both the expected protective effects of vaccination as well as possible post-vaccine adverse effects. Our study illustrates the power of systems biology approaches in improving our understanding of the comprehensive biological response to vaccination against COVID-19.
新冠疫苗是减少全球范围内严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染影响的重要工具,除了能预防40%至65%的有症状疾病外,还能预防80%至90%因再次感染导致的住院和死亡。然而,全球人口同时大规模接种疫苗无疑会揭示免疫反应以及发生疫苗接种后不良事件倾向的异质性,尤其是在易感个体中。在此,我们应用了一种系统生物学工作流程,将疫苗转录特征与化学基因组学相结合,以研究mRNA疫苗的药理作用。首先,我们推导转录特征,并使用通路富集和网络方法预测其生物学效应。其次,我们查询连通图(CMap)以确定不良事件假设的优先级。最后,我们接受由独立方法预测的可信度更高的假设。我们的结果表明,基于mRNA的BNT162b2疫苗会影响与干扰素和细胞因子信号传导相关的免疫反应通路,这应会带来疫苗接种的成功,但也可能导致一些不良事件。我们的结果强调了BNT162b2对钙稳态的影响,这可能是一些与mRNA疫苗相关的常见不良事件的原因。值得注意的是,CMap查询结果显示了心脏副作用。总之,我们的方法确定了疫苗接种预期保护作用以及可能的疫苗接种后不良作用的潜在机制。我们的研究说明了系统生物学方法在增进我们对新冠疫苗接种综合生物学反应理解方面的作用。